Kiniksa Pharmaceuticals (KNSA)

• Market cap: $4.03B
• 1 day: 0.87%
• 5 days: 5.35%
• 1 month: -7.38%
• 3 months: 12.56%
• 6 months: 25.97%
• Year to date: 24.59%
• 1 year: 84.23%
• 5 years: 258.25%
• 10 years: 168.82%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.

Employees: 366